0.7599
price up icon6.34%   0.0453
after-market After Hours: .73 -0.0299 -3.93%
loading
Tempest Therapeutics Inc stock is traded at $0.7599, with a volume of 631.79K. It is up +6.34% in the last 24 hours and down -6.12% over the past month. Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$0.7146
Open:
$0.7045
24h Volume:
631.79K
Relative Volume:
0.73
Market Cap:
$31.19M
Revenue:
-
Net Income/Loss:
$-31.11M
P/E Ratio:
-0.4967
EPS:
-1.53
Net Cash Flow:
$-28.18M
1W Performance:
-5.15%
1M Performance:
-6.12%
6M Performance:
-43.29%
1Y Performance:
-85.07%
1-Day Range:
Value
$0.70
$0.7599
1-Week Range:
Value
$0.70
$0.84
52-Week Range:
Value
$0.6986
$5.33

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name
Name
Tempest Therapeutics Inc
Name
Phone
415-798-8589
Name
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Name
Employee
17
Name
Twitter
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
TPST's Discussions on Twitter

Compare TPST with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TPST
Tempest Therapeutics Inc
0.7599 31.19M 0 -31.11M -28.18M -1.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-14-24 Initiated Scotiabank Sector Outperform
Feb-08-24 Initiated Jefferies Buy

Tempest Therapeutics Inc Stock (TPST) Latest News

pulisher
05:14 AM

Virtu Financial LLC Purchases Shares of 43,105 Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

05:14 AM
pulisher
Mar 31, 2025

FY2028 Earnings Estimate for TPST Issued By William Blair - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Estimate for TPST Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Scotiabank Has Lowered Expectations for Tempest Therapeutics (NASDAQ:TPST) Stock Price - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Scotiabank Lowers Tempest Therapeutics (NASDAQ:TPST) Price Target to $7.00 - Armenian Reporter

Mar 30, 2025
pulisher
Mar 30, 2025

HC Wainwright Has Lowered Expectations for Tempest Therapeutics (NASDAQ:TPST) Stock Price - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Tempest Therapeutics Advances Cancer Therapies Amid Financial Challenges - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

H.C. Wainwright cuts Tempest Therapeutics stock target to $16 By Investing.com - Investing.com UK

Mar 28, 2025
pulisher
Mar 27, 2025

Tempest Therapeutics Inc. (TPST) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

Why Super Micro Computer Stock Was Sliding This Week - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

Tempest Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Tempest's Cancer Drug Shows 6-Month Survival Gain, Lands Major Roche Partnership - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Tempest Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView

Mar 26, 2025
pulisher
Mar 25, 2025

Tempest Announces Amezalpat Poster Presentation at the 2025 - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Breakthrough Cancer Drug Data Reveals New Immune Response Findings at AACR 2025 - Stock Titan

Mar 25, 2025
pulisher
Mar 13, 2025

Tempest Therapeutics advances Phase 2 trial for cancer prevention By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

FDA Study May Proceed Notice Received for Phase 2 Trial of - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Tempest Therapeutics Says Familial Adenomatous Polyposis Trial Gets US FDA 'Study May Proceed' Notice - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Tempest Therapeutics advances Phase 2 trial for cancer prevention - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Tempest gets FDA nod to begin mid-stage study of its therapy for colon cancer-causing genertic condition - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

FDA Green Light: Tempest's Revolutionary FAP Drug Advances to Phase 2 with NCI Backing - StockTitan

Mar 13, 2025
pulisher
Mar 11, 2025

Tempest Therapeutics (TPST) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Mar 11, 2025
pulisher
Mar 07, 2025

Tempest Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:TPST - Benzinga

Mar 07, 2025
pulisher
Mar 01, 2025

Comparing Tempest Therapeutics (NASDAQ:TPST) & Nkarta (NASDAQ:NKTX) - Defense World

Mar 01, 2025
pulisher
Feb 17, 2025

Tempest Therapeutics, Inc. (NASDAQ:TPST) Sees Significant Decrease in Short Interest - Defense World

Feb 17, 2025
pulisher
Feb 11, 2025

TPST stock rated a Sector outperform by Scotiabank - Knox Daily

Feb 11, 2025
pulisher
Feb 11, 2025

Tempest gets fast track designation from FDA for amezalpat - MSN

Feb 11, 2025
pulisher
Feb 11, 2025

A closer look at Tempest Therapeutics Inc (TPST)’s stock price trends - US Post News

Feb 11, 2025
pulisher
Feb 11, 2025

Tempest Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation to Amezalpat (TPST-1120) - Marketscreener.com

Feb 11, 2025
pulisher
Feb 10, 2025

Tempest Therapeutics Inc (TPST) Shares Rise Despite Market Challenges - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Tempest Therapeutics Says Amezalpat Receives US FDA Fast Track Status As Treatment for Liver Cancer - Marketscreener.com

Feb 10, 2025
pulisher
Feb 10, 2025

Tempest Granted Fast Track Designation From The U.S. Food And Drug Administration For Amezalpat - Marketscreener.com

Feb 10, 2025
pulisher
Feb 10, 2025

Tempest Granted Fast Track Designation from the U.S. Food - GlobeNewswire

Feb 10, 2025
pulisher
Feb 10, 2025

Tempest's Liver Cancer Breakthrough: FDA Fast-Tracks Drug Showing 6-Month Survival Gain - Stock Titan

Feb 10, 2025
pulisher
Feb 07, 2025

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 07, 2025
pulisher
Feb 07, 2025

Tempest Therapeutics Awards Strategic Compensation Package: Inside the 4-Year Vesting Deal - StockTitan

Feb 07, 2025
pulisher
Feb 04, 2025

Analyzing Ratios: Tempest Therapeutics Inc (TPST)’s Financial Story Unveiled - The Dwinnex

Feb 04, 2025
pulisher
Feb 04, 2025

A stock that deserves closer examination: Tempest Therapeutics Inc (TPST) - US Post News

Feb 04, 2025
pulisher
Jan 27, 2025

Tempest Therapeutics Inc (NASDAQ: TPST) – An Analysis Is What You Need - Stocks Register

Jan 27, 2025
pulisher
Jan 14, 2025

Tempest Therapeutics, Inc. (NASDAQ:TPST) Shares Acquired by Geode Capital Management LLC - Defense World

Jan 14, 2025
pulisher
Jan 06, 2025

Tempest Receives Orphan Drug Designation from the U.S. Food - GlobeNewswire

Jan 06, 2025
pulisher
Jan 06, 2025

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) - GlobeNewswire Inc.

Jan 06, 2025
pulisher
Jan 02, 2025

Before You Sell Tempest Therapeutics Inc (NASDAQ: TPST) Shares, Here’sWhat You Need To Know. - Stocks Register

Jan 02, 2025
pulisher
Dec 30, 2024

Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register

Dec 30, 2024
pulisher
Dec 14, 2024

TPST Stock Touches 52-Week Low at $0.8 Amid Market Challenges - Investing.com Canada

Dec 14, 2024
pulisher
Dec 13, 2024

TPST Stock Touches 52-Week Low at $0.8 Amid Market Challenges By Investing.com - Investing.com South Africa

Dec 13, 2024
pulisher
Dec 10, 2024

Thinking about buying stock in Nikola, Delcath Systems, Taysha G - GuruFocus.com

Dec 10, 2024
pulisher
Dec 06, 2024

Tempest Therapeutics amends rights agreement By Investing.com - Investing.com Australia

Dec 06, 2024
pulisher
Dec 06, 2024

Tempest Therapeutics amends rights agreement - Investing.com India

Dec 06, 2024
pulisher
Dec 06, 2024

Tempest Therapeutics Awards Key Employee Stock Options in Strategic Compensation Move | TPST Stock News - StockTitan

Dec 06, 2024
pulisher
Nov 27, 2024

Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock - Yahoo Finance

Nov 27, 2024

Tempest Therapeutics Inc Stock (TPST) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):